Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.RNAC · Entity 6015 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,133 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 2,600 · Balance 11,133 F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.76 · Expires 2036-01-01 | Direct | 7,800 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 7,800 · Balance 7,800 |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACCELERON PHARMA INC
Report date November 19, 2021 · Filed November 22, 2021
Section 16 reporting ended · disclosed 2021-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Other · Disposed 1,622 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $52.61 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 17,956 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $115.53 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 3,222 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 21:19 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $6.76 | $0.00 |
DisclosureSEC source: 0001453687-26-000037 · wk-form4_1767734348.xml · derivative · entry 2 Malik Kemal · CIK 0001797921 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2036-01-01 Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:19 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantCommon Stock | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-26-000037 · wk-form4_1767734348.xml · nonDerivative · entry 1 Malik Kemal · CIK 0001797921 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,133 F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:19 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $16.93 | $0.00 |
DisclosureSEC source: 0001453687-25-000019 · wk-form4_1736198381.xml · derivative · entry 2 Malik Kemal · CIK 0001797921 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2035-01-01 Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:19 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantCommon Stock | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-25-000019 · wk-form4_1736198381.xml · nonDerivative · entry 1 Malik Kemal · CIK 0001797921 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,533 F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2026. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:10 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 7,600 | $0.00 Strike: $24.27 | $0.00 |
DisclosureSEC source: 0001453687-24-000093 · wk-form4_1720037414.xml · derivative · entry 2 Malik Kemal · CIK 0001797921 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,600 Underlying: Common Stock · 7,600 shares Expires 2034-06-30 F2 · derivative.exercise_date: This award will vest in 36 equal monthly installments, so that it shall be fully vested on July 1, 2027. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:10 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantCommon Stock | 5,933 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-24-000093 · wk-form4_1720037414.xml · nonDerivative · entry 1 Malik Kemal · CIK 0001797921 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,933 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in three equal annual installments following the date of grant so that the underlying shares will be fully vested on July 1, 2027. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:11 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 3,222 | Not disclosed Strike: $115.53 | Not disclosed |
DisclosureSEC source: 0001104659-21-142279 · tm2133601-12_4seq1.xml · derivative · entry 3 Malik Kemal · CIK 0001797921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,222 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:11 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 17,956 | Not disclosed Strike: $52.61 | Not disclosed |
DisclosureSEC source: 0001104659-21-142279 · tm2133601-12_4seq1.xml · derivative · entry 2 Malik Kemal · CIK 0001797921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,956 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:11 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | OtherCommon Stock | 1,622 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-142279 · tm2133601-12_4seq1.xml · nonDerivative · entry 1 Malik Kemal · CIK 0001797921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 18:46 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 3,222 | $0.00 Strike: $115.53 | $0.00 |
DisclosureSEC source: 0001179110-21-001111 · edgar.xml · derivative · entry 2 Malik Kemal · CIK 0001797921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,222 Underlying: Common Stock · 3,222 shares Expires 2031-01-29 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 18:46 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 1,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001111 · edgar.xml · nonDerivative · entry 1 Malik Kemal · CIK 0001797921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,622 Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:24 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 17,567 | $0.00 Strike: $52.61 | $0.00 |
DisclosureSEC source: 0001179110-20-000266 · edgar.xml · derivative · entry 1 Malik Kemal · CIK 0001797921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,567 Underlying: Common Stock · 17,567 shares Expires 2030-01-02 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal quarterly installments over the first three years after January 1, 2020. Read SEC document |
| January 02, 2020 Filed Feb 10, 2020 17:50 UTC Amendment | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 17,956 | $0.00 Strike: $52.61 | $0.00 |
DisclosureSEC source: 0001179110-20-001408 · edgar.xml · derivative · entry 1 Malik Kemal · CIK 0001797921 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,956 Underlying: Common Stock · 17,956 shares Expires 2030-01-02 F1 · shares: Due to a clerical error, the original Form 4 filed on January 3, 2020 listed the incorrect number of securities in columns 5, 7 and 9 of Table II. F2 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal quarterly installments over the first three years after January 1, 2020. F1 · derivative.underlying_shares: Due to a clerical error, the original Form 4 filed on January 3, 2020 listed the incorrect number of securities in columns 5, 7 and 9 of Table II. F1 · balance_after: Due to a clerical error, the original Form 4 filed on January 3, 2020 listed the incorrect number of securities in columns 5, 7 and 9 of Table II. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.